Skip to content

News

Bevacizumab with Chemo Improves Survival in Ovarian Cancer ...

Bevacizumab with Chemo Improves Survival in Ovarian Cancer with Poor Prognosis

(July 1, 2015) When bevacizumab was added to standard chemotherapy, ovarian cancer patients with a poor prognosis had an overall survival benefit, according to the ICON7 study published online this week in journal The Lancet Oncology. The study enrolled 1,528 women with newly diagnosed ovarian cancer, high-risk early-stage disease or more advanced disease. The patients were … Continued

ASCO 2015 Update

ASCO 2015 Update

Several promising advances in the treatment of ovarian cancer were presented at this year’s annual meeting of the American Society of Clinical Oncologists (ASCO). Below is a report from one of our Research Advocates, Katie Hoody. Click the plus sign to read Katie's report.

OCRF Researchers Find Clues on Mucinous Ovarian Cancer Origins

OCRF Researchers Find Clues on Mucinous Ovarian Cancer Origins

(June 19, 2015) In a recent study, funded in part by OCRF grants to Dr. Simon Gayther and Dr. Andrew Berchuck, researchers have made important breakthroughs toward understanding the risk and growth of a certain kind of ovarian cancer, known as mucinous ovarian carcinoma, or MOC. The international study involving 1,644 women with MOC and … Continued

Investigators Discover How Ovarian Cancer Halts Body’...

Investigators Discover How Ovarian Cancer Halts Body’s Natural Defense Against Tumor

(June 18, 2015) A team of researchers, including OCRF grantees Juan Cubillos-Ruiz, PhD, and Alfredo Perales-Puchalt, MD, have discovered how ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor. The findings are published in the June 11 issue of Cell. A therapy that … Continued

Ovarian Cancers Sensitive to Chemo Identified by Gene Mutat...

Ovarian Cancers Sensitive to Chemo Identified by Gene Mutations

(June 17, 2015) Researchers at MD Anderson Cancer Center in Houston have identified a new class of gene mutations that may contribute to outcomes in the treatment of ovarian cancer. Research on the gene family known as ADAMTS could open up a new genetic avenue for the design of ovarian cancer therapies. The findings were … Continued

Ovarian Cancer News from ASCO

Ovarian Cancer News from ASCO

(June 5, 2015) The Society of Gynecologic Oncology has posted three short videos on YouTube that highlight some of the ovarian cancer research findings presented at the American Society of Clinical Oncology annual meeting last week. Click here to watch the videos, which highlight the results of a number of ovarian cancer clinical trials.

Whole-Genome Characterization of Chemoresistant Ovarian Cancer

Whole-Genome Characterization of Chemoresistant Ovarian Cancer

(May 28, 2015) In an effort to study treatment options for high-grade serous ovarian cancer, scientists from the University of Queensland and Sydney’s Millennium Institute collected DNA from 92 patients to find out what makes those cells so resistant to chemotherapy.  OCRF Scientific Advisory Committee members Ronny Drapkin, MD, PhD, and Ernst Lengyel, MD, PhD, … Continued

Chemo Before Surgery Leads to Better Outcomes

Chemo Before Surgery Leads to Better Outcomes

(May 28, 2015) A recent study performed in the UK and New Zealand revealed that having chemotherapy treatments before and after surgery is associated with a higher quality of life when compared to those who undergo surgery before chemotherapy. The study, which included 550 women with Stage III or IV ovarian cancer, concluded that shrinking … Continued

Rosalind Franklin Excellence in Ovarian Cancer Research Award

Rosalind Franklin Excellence in Ovarian Cancer Research Award

Introducing the 2015 Ovarian Cancer National Conference Rosalind Franklin Excellence in Ovarian Cancer Research Award winner: Beth Karlan, MD. The Rosalind Franklin Excellence in Ovarian Cancer Research Award is named for the molecular biologist Dr. Rosalind Elsie Franklin, who played a vital role in discovering the structure of DNA. Her career was cut short in 1958 when she died of ovarian cancer at age 37. Throughout her life, she was a committed researcher; this award honors an individual who continues her legacy of excellence. Beth Karlan, MD is the Director of the Cedars-Sinai Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, and Director of the Gilda Radner Hereditary Cancer Program. Click the plus sign to read more.

AACR Update

AACR Update

Research Advocate Seana Roubinek attended the 2015 American Association of Cancer Research Annual Meeting in April.  Here is her report:  “As a two-time cancer ovarian cancer survivor, I have had the great opportunity to get involved in legislative advocacy as well as the Survivors Teaching Students® program through the Ovarian Cancer National Alliance. Being selected … Continued

New Screening Approach Shows Promise

New Screening Approach Shows Promise

(May 5, 2015) Data from a large clinical trial shows that a personalized method for interpreting blood tests identifies more ovarian cancer cases than a generalized approach. The results from the study will be published in the Journal of Clinical Oncology. Using an algorithm to analyze changes in the level of CA-125 (a protein in … Continued

Oophorectomy Increases Breast Cancer Survival in BRCA1 Muta...

Oophorectomy Increases Breast Cancer Survival in BRCA1 Mutation Carriers

(April 29, 2015) A study published in JAMA Oncology last Saturday concluded that an oophorectomy, the surgery to remove ones ovaries, has a substantial impact on survival rates for those diagnosed with stage I or II breast cancer who also tested positive for the BRCA1 mutation. Involved in the study were 676 women, 345 of whom had … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.